Memantine Hydrochloride Tablets USP, 5 mg, are supplied as orange colored, oblong, biconvex, film-coated tablets debossed “IP 173” on one side and plain on the other side.
Memantine is a medicine for dementia. It is used to treat memory loss which is one of the main symptoms of dementia. It is also used to treat the symptoms of: Alzheimer's disease.
What is Ebixa used for? Ebixa is used to treat patients with moderate to severe Alzheimer's disease. Alzheimer's disease is a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour. The medicine can only be obtained with a prescription.
Is memantine effective for all people with dementia? Memantine will not help everyone who takes it. It treats the symptoms of moderate to severe Alzheimer's disease only and is not a cure – there is no evidence that it can halt or reverse the process of cell damage that causes the disease.
Memantine 10mg tablets are white to off white coloured, approximately 11 x 6 mm, oval shaped, film-coated tablets, debossed with “10” on one side and “breakline” on the other side.
Among the antidementia drugs, only memantine has a sedative effect. In addition, it also has the effect of prolonging sleep time.
Memantine has been used successfully in treating conditions such as complex regional pain syndrome, phantom limb pain, fibromyalgia, and postmastectomy pain.
Memantine Helps Prevent Agitation, Aggressive Behavior in Moderate-to-Severe AD, Improves Appetite.
For oral dosage form (delayed-release capsules): For moderate to severe Alzheimer's disease: Adults—One capsule once a day at bedtime. Children—Use and dose must be determined by your doctor.
It works by decreasing abnormal activity in the brain. Memantine may improve the ability to think and remember or may slow the loss of these abilities in people who have AD. However, memantine will not cure AD or prevent the loss of these abilities at some time in the future.
Memantine has a small beneficial effect in people with moderate-to-severe AD. This benefit affects thinking, the ability to carry on normal daily activities, and the severity of behaviour and mood problems.
Administration: The examiner reads a list of 5 words at a rate of one per second, giving the following instructions: “This is a memory test. I am going to read a list of words that you will have to remember now and later on. Listen carefully. When I am through, tell me as many words as you can remember.
Donepezil (also known as Aricept), rivastigmine (Exelon) and galantamine (Reminyl) are used to treat the symptoms of mild to moderate Alzheimer's disease. Donepezil is also used to treat more severe Alzheimer's disease.
Memantine can take up to 3 months to begin working, but this will vary from person to person. You will get a follow-up appointment so your doctor can check how well the medicine is working.
Adults—At first, 5 milligrams (mg) once a day. Your doctor may gradually increase your dose as needed. However, the dose is usually not more than 10 mg two times a day.
The patient is agitated and aggressive at treatment start, and gradually worsens during memantine increase up to 20 mg. The drug is discontinued approximately after 5 weeks since its introduction. De novo agitation develops immediately after the first 5-mg doses.
Anxiety Disorders
An open-label trial and a single-blind case-control study both showed improvement in patients with OCD receiving treatment with memantine.
However, there are various symptoms of behavioral disturbances, such as delusion, hallucination, agitation/aggression, dysphoria, anxiety/phobia, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity/activity disturbances, nighttime disturbance/diurnal rhythm disturbances, and eating ...
Memantine and donepezil combination is used to treat dementia (memory loss and mental changes) associated with moderate or severe Alzheimer's disease. Memantine and donepezil will not cure Alzheimer's disease, however, it may improve thinking ability, behavior, or functional ability.
One potential non-opioid receptor treatment is memantine. Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist that is approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer's disease (Namenda [package insert], 2013).
Memantine decreases food intake without inducing abdominal discomfort and anxiety, suggesting that this compound would be a good candidate drug for obesity control. However, the molecular mechanism and brain circuit involved in the regulation of weight loss by memantine need further study.
Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off‐label for mild AD.